Androgens, aging, and prostate health

Welén, Karin; Damber, Jan‐Erik

doi:10.1007/s11154-022-09730-z

Cited by 15 publications

(6 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These effects result in an increase in the number of cells and eventually lead to the development of BPH. 416 Changes in androgen levels and tissue remodeling caused by aging are generally considered to be the major determinants of BPH. There is clinical evidence that taking a 5α-reductase inhibitor can reduce the concentration of dihydrotestosterone in prostate tissue, thereby preventing the further development of BPH.…”

Section: Osteoarthritis (Oa)mentioning

confidence: 99%

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Guo

Huang

Dou

et al. 2022

Sig Transduct Target Ther

350

160

View full text Add to dashboard Cite

Aging is a gradual and irreversible pathophysiological process. It presents with declines in tissue and cell functions and significant increases in the risks of various aging-related diseases, including neurodegenerative diseases, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, and immune system diseases. Although the development of modern medicine has promoted human health and greatly extended life expectancy, with the aging of society, a variety of chronic diseases have gradually become the most important causes of disability and death in elderly individuals. Current research on aging focuses on elucidating how various endogenous and exogenous stresses (such as genomic instability, telomere dysfunction, epigenetic alterations, loss of proteostasis, compromise of autophagy, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, deregulated nutrient sensing) participate in the regulation of aging. Furthermore, thorough research on the pathogenesis of aging to identify interventions that promote health and longevity (such as caloric restriction, microbiota transplantation, and nutritional intervention) and clinical treatment methods for aging-related diseases (depletion of senescent cells, stem cell therapy, antioxidative and anti-inflammatory treatments, and hormone replacement therapy) could decrease the incidence and development of aging-related diseases and in turn promote healthy aging and longevity.

show abstract

Section: Osteoarthritis (Oa)mentioning

confidence: 99%

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Guo

Huang

Dou

et al. 2022

Sig Transduct Target Ther

350

160

View full text Add to dashboard Cite

show abstract

“…Supraphysiological doses of androgens can increase muscle size and strength 23 . However, there is an increased risk of prostate enlargement and prostate cancer 24 . In summary, hormone replacement therapy is associated with significant side effects and its use in sarcopenia is limited.…”

Section: Current Treatments For Sarcopeniamentioning

confidence: 99%

Potential application of anti-osteoporotic therapy to relieve sarcopenia in the elderly

Li,

Kong

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Sarcopenia is a progressive and systemic skeletal muscle disorder associated with aging that- usually occurs with age in the elderly.Sarcopenia currently lacks effective pharmacological treatment modalities. Multiple pharmacological intervention modalities are available for osteoporosis, a comprehensive disease characterized by decreased systemic bone mass, degradation of bone microarchitecture, and increased bone fragility. Several recent studies have shown an extremely strong correlation between sarcopenia and osteoporosis, leading to the concept of “osteosarcopenia”. Therefore, it is possible to alleviate sarcopenia simultaneously by improving osteoporosis.

show abstract

“…It is transported to the target tissues in the body through binding of sex hormone binding globulin (SHBG) in the blood to function [15]. It is an important androgen that promotes human growth and development, and maintains normal organ function [16,17]. Obesity is a risk factor for OA, and studies have shown that testosterone de ciency can lead to obesity and insulin resistance, while testosterone therapy can inhibit fat deposition and reduce insulin resistance [18].…”

Section: Introductionmentioning

confidence: 99%

The causal impact of bioavailable testosterone levels on osteoarthritis: a bidirectional Mendelian randomized study Running Title: Causality of testosterone on OA in bidirectional MR study

Jiang,

Yao,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: It has been shown that low testosterone levels are associated with the development of osteoarthritis (OA). In our study, we aimed to investigate a bidirectional causal relationship between bioavailable testosterone levels and OA using Mendelian randomization (MR) analysis. Methods: In our study, the datasets from publicly available genome-wide association study (GWAS) were adopted, including the OA-related dataset (ukb-b-14486) and the bioavailable testosterone levels-related dataset (ebi-a-GCST90012104). In total, five methods were utilized, namely MR Egger, Weighted median, Inverse variance weighted (IVW), Simple mode, and Weighted mode. Among them, IVW was the main analytical method. Additionally, the sensitivity analysis was carried out through the heterogeneity test, the horizontal pleiotropy test, and the Leave-One-Out (LOO) method. Results: The result of forward MR analysis demonstrated that bioavailable testosterone levels were considerably relevant to OA, and were a risk factor for OA (OR = 1.009, 95% CI: 1.001-1.017, P = 0.020). However, through reverse MR analysis, we did not find a causal relationship between OA and bioavailable testosterone levels. Moreover, the results of the sensitivity analysis suggested that our results were reliable. Conclusion: The results of our study supported a causal relationship between bioavailable testosterone levels and OA.

show abstract

Androgens, aging, and prostate health

Cited by 15 publications

References 160 publications

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments

Potential application of anti-osteoporotic therapy to relieve sarcopenia in the elderly

The causal impact of bioavailable testosterone levels on osteoarthritis: a bidirectional Mendelian randomized study Running Title: Causality of testosterone on OA in bidirectional MR study

Contact Info

Product

Resources

About